Revenue ($USD) : $730,230,000
R&D spend : $145,647,000
Employees : 1,468
Fiscal year end : 12/31/2023
CEO : Isaac Zacharias, president (former CEO Douglas Godshall exited when J&J closed its acquisition)

www.shockwavemedical.com

Shockwave Medical’s proprietary intravascular lithotripsy (IVL) tech delivers local sonic pressure waves to treat calcified plaque, fracturing calcium while reducing the risk of complications. Shockwave launched its new IVL catheter in October 2023 following FDA clearance. Johnson & Johnson purchased the company for $13.1 billion in May 2024, so this will be the company’s last year on the Medtech Big 100 as an independent company. Shockwave first made our list at No. 99 in 2022. –SW

MORE AT MDO: Can Shockwave crack the code for FDA approval of its Reducer implant?